Target intelligence / Profile preview

60S ribosomal protein L37 (RPL37)

Target
RPL37
Molecular classification
Other, Ribosomal protein, Structural protein
01

Overview

60S ribosomal protein L37 is a structural component of the large (60S) subunit of cytoplasmic ribosomes, which are the cellular complexes responsible for catalyzing protein synthesis in eukaryotes[1][2][3]. It is encoded by the RPL37 gene and contains a characteristic C2C2-type zinc finger-like motif[1][4]. RPL37's primary role is as a structural constituent of the ribosome, but like some ribosomal proteins, it may also interact with cellular regulatory proteins such as MDM2/MDMX, thereby potentially linking ribosome biogenesis to cell cycle regulation and tumor suppression pathways[2][7]. Diseases associated with defects in RPL37 include Diamond-Blackfan anemia and certain types of cataract[3]. Several antibiotics—such as puromycin and anisomycin—can interact with ribosomal proteins, inhibiting translation and thus protein synthesis[2]. There are no established therapeutic drugs directly and selectively targeting RPL37 given its ubiquitous and essential role in normal cells.

Other names
Large ribosomal subunit protein eL3760S ribosomal protein L37G1.16(gene: RPL37)
02

Mechanism of action

Inhibition of protein synthesis (by interfering with ribosome function for certain antibiotics)[2]

03

Biological functions

Protein synthesisTranslationStructural constituent of ribosomeRNA bindingrRNA bindingMetal ion binding
04

Disease associations

CancerDiamond-Blackfan anemiaCataract (multiple types)Other
05

Safety considerations

Essential for global protein synthesis—targeting may cause widespread cytotoxicity and unintended cell deathribosomopathies if mutated
06

Interacting drugs

Puromycin

4 more in the full profile.

Beyond the preview

Go deeper on 60S ribosomal protein L37 (RPL37).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60S ribosomal protein L37 (RPL37).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call